Expression levels of GSDMB and ORMDL3 are associated with relapsing-remitting multiple sclerosis and IKZF3 rs12946510 variant

被引:0
|
作者
Stefanovic, Milan [1 ]
Stojkovic, Ljiljana [1 ]
Zivotic, Ivan [1 ]
Dincic, Evica [2 ]
Stankovic, Aleksandra [1 ]
Zivkovic, Maja [1 ]
机构
[1] Univ Belgrade, Inst Nucl Sci Vinea Natl Inst Republ Serbia, Lab Radiobiol & Mol Genet 080, POB 522, Belgrade 11000, Serbia
[2] Mil Med Acad, Clin Neurol, Belgrade, Serbia
关键词
Multiple sclerosis; ORMDL3; GSDMB; IKZF3; 17q12-21; rs12946510; DNA METHYLATION; ORMDL3; AIOLOS; DISABILITY; INSIGHTS;
D O I
10.1016/j.heliyon.2024.e25033
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Multiple sclerosis (MS), a noncurable autoimmune neurodegenerative disease, requires constant research that could improve understanding of both environmental and genetic factors that lead to its occurrence and/or progression. Recognition of the genetic basis of MS further leads to an investigation of the regulatory role of genetic variants on gene expression. Among risk variants for MS, Ikaros zinc finger 3 (IKZF3) gene variant rs12946510 was identified as one of the top -ranked and the expression quantitative trait loci (eQTL) for genes residing in chromosomal locus 17q1221. The study aimed to investigate the association of gene expression of the immunologically relevant genes, which map to indicated locus, ORMDL3, GSDMB, and IKZF3, with MS and rs12946510 genotype, taking into account disease phase, clinical parameters of disease progression, and severity and immunomodulatory therapy. We used TaqMan (R) technology for both allelic discrimination and gene expression determination in 67 relapsing MS patients and 50 healthy controls. Decreased ORMDL3 and GSDMB mRNA levels had significant associations with MS and rs12946510 TT rare homozygote among patients. Significant positive correlations between ORMDL3 and GSDMB mRNA expression were observed in both patients and controls. We detected the significant between -effect of sex and rs12946510 on the expression of ORMDL3 in the patient group and interferon beta therapy and rs12946510 on GSDMB expression. Our results show the association of ORMDL3 and GSDMB mRNA expression with the clinical manifestation of MS and confirm that IKZF3 rs12946510 exerts the eQTL effect on both genes in multiple sclerosis. Besides providing novel insight related to MS phases and interferon beta therapy, the study results confirm previous studies on regulatory genetic variants, autoimmunity, and MS.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Brain atrophy and fatigue in relapsing-remitting multiple sclerosis patients: a 3T study
    Bisecco, A.
    Gallo, A.
    Sacco, R.
    Della Corte, M.
    Docimo, R.
    Cirillo, M.
    Corbo, D.
    Lavorgna, L.
    Cirillo, S.
    Bonavita, S.
    Esposito, F.
    Tedeschi, G.
    JOURNAL OF NEUROLOGY, 2011, 258 : 152 - 152
  • [22] INTEGRIN SUBUNIT ALPHA 4 (ITGA4) VARIANT IS ASSOCIATED WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN AN IRANIAN POPULATION
    Taheri, Mohammad
    Noroozi, Rezvan
    Sayad, Arezou
    Ghafouri-Fard, Soudeh
    Omrani, Mir Davood
    ACTA MEDICA MEDITERRANEA, 2018, 34 (01): : 83 - 86
  • [23] Immunogenicity with peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis: 2-year data from the randomised phase 3, multicentre ADVANCE study in relapsing-remitting multiple sclerosis
    White, J. T.
    Kieseier, B. C.
    Newsome, S. D.
    Zhu, Y.
    Cui, Y.
    Seddighzadeh, A.
    Hung, S.
    Deykin, A.
    Subramanyam, M.
    JOURNAL OF NEUROLOGY, 2014, 261 : S234 - S234
  • [24] Immunogenicity with peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis: 2-year data from the randomised phase 3, multicentre ADVANCE study in relapsing-remitting multiple sclerosis
    White, J. T.
    Kieseier, B. C.
    Newsome, S. D.
    Zhu, Y.
    Cui, Y.
    Seddighzadeh, A.
    Hung, S.
    Deykin, A.
    Subramanyam, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 346 - 346
  • [25] The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis
    Frisullo, Giovanni
    Mirabella, Massimiliano
    Angelucci, Francesco
    Caggiula, Marcella
    Morosetti, Roberta
    Sancricca, Cristina
    Patanella, Agata Katia
    Nociti, Viviana
    Lorio, Raffaele
    Bianco, Assunta
    Tomassini, Valentina
    Pozzilli, Carlo
    Tonali, Pietro Attilio
    Matarese, Giuseppe
    Batocchi, Anna Paola
    JOURNAL OF NEUROIMMUNOLOGY, 2007, 192 (1-2) : 174 - 183
  • [26] Natalizumab is effective in relapsing-remitting multiple sclerosis patients with advanced disease severity over 3 years
    Kallweit, U.
    Jelcic, I.
    Braun, N.
    Fischer, H.
    Zoerner, B.
    Schreiner, B.
    Sokolov, A.
    Linnebank, M.
    ALLERGOLOGIE, 2011, 34 (02) : 115 - 115
  • [27] Fewer LAG-3+ T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes
    Jones, Britta E.
    Maerz, Megan D.
    Bahnson, Henry T.
    Somasundaram, Ashwin
    McCarthy, Lucas H.
    Speake, Cate
    Buckner, Jane H.
    JOURNAL OF IMMUNOLOGY, 2022, 208 (03): : 594 - 602
  • [28] Inflammatory cytokines in relapsing-remitting multiple sclerosis (RRMS) patients (vol 3, pg 741, 2014)
    Shajarian, M.
    Alsahebfosoul, F.
    Etemadifar, M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2015, 4 (02) : 180 - 180
  • [29] 3′UTR C2370A allele of the IL-23 receptor gene is associated with relapsing-remitting multiple sclerosis
    Illes, Zsolt
    Safrany, Eniko
    Peterfalvi, Agnes
    Magyari, Lili
    Farago, Bernadett
    Pozsonyi, Eva
    Rozsa, Csilla
    Komoly, Samuel
    Melegh, Bela
    NEUROSCIENCE LETTERS, 2008, 431 (01) : 36 - 38
  • [30] Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial
    Maehler, Anja
    Steiniger, Jochen
    Bock, Markus
    Klug, Lars
    Parreidt, Nadine
    Lorenz, Mario
    Zimmermann, Benno F.
    Krannich, Alexander
    Paul, Friedemann
    Boschmann, Michael
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2015, 101 (03): : 487 - 495